Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$39.30
▲ $0.51 (+1.3%)
Market data updated: 09/25 08:25 AM
Fundamentals updated: 09/24/2026
News analyzed: 09/25/2026
Market Cap
$2.01B
Day Range
$38.39 - $39.40
52-Week Range
$28.95 - $49.32
Beta
—
Next Earnings
04.11.2026
Support
$37.35
Resistance
$49.32
VCEL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+24.3% (1Y)
Strengths: 11/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 60.0%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $10.70 vs. price $39.30 (-72.8%)
Fair Value
Signal tension
Growth scores strong (79/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
79
Quality
58
Value
33
Momentum
43
Risk
48
Sentiment
100
Fundamental
54
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Vericel Corporation (NASDAQ: VCEL) has primarily focused on its strong financial performance and investor appeal, particularly through growth and valuation analyses. Analysts repeatedly highlight its favorable position in the "affordable growth" category, citing robust earnings per share (EPS) and revenue growth alongside a reasonable valuation compared to biotech peers. Multiple firms, including TD Cowen and Truist Securities, have maintained a "Buy" rating while raising their price targets to $58, reflecting optimism about its stock potential. The company’s profitability and technical trading strength have also been emphasized as key strengths.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Vericel Corporation. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
31
🎯 Conviction (vs. Emotion)
41
Psychology
45
Fundamentals
54
Technical
43
Valuation
33
The price rise has far outpaced the actual improvement in fundamental data.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
-16%
Market Narrative
73
Fundamental Reality
41
Narrative Gap
+32
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant anchoring behavior suggests traders are fixated on the 2.1% proximity to support, likely due to recent price action. Overconfidence (45) and euphoria (35) persist despite weak momentum, driven by extreme valuation (+276% DCF) and positive sentiment (100/100). The narrative gap (27) hints at a disconnect between optimistic expectations and market reality. The key question: will traders break from anchoring if support is tested, or will overconfidence sustain despite lagging fundamentals?
Updated: 09/08/2026, 12:13 AM
What could change this?
👥 What the crowd believes
"Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference"
"fits the Affordable Growth screen with high growth/profitability scores"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Benjamin Graham — 18/100
🗣️ Why do they disagree?
Based on each investor's documented principles, the model estimates that Walter Bagehot sees VCEL's strong liquidity and rates it highly, while Philip Fisher and Jack Schwager view the company as solid with respectable growth and risk‑reward but not outstanding. The more cycle‑aware and crowd‑sentiment thinkers such as Samuel Nelson, Charles Mackay, and Thorstein Veblen assign middling scores, reflecting mixed signals about growth translating to profit and a neutral position in the market cycle. Value‑oriented frameworks like Benjamin Graham (both defensive and enterprising), Howard Marks, and the efficient‑market view of Malkiel & Bogle give low scores, flagging valuation, margin‑of‑safety and risk concerns. Consequently, the methodologies diverge: liquidity‑focused and growth‑oriented scores cluster in the 60‑100 range, whereas safety‑ and valuation‑focused approaches cluster below 50, leading to an overall mixed but cautious assessment.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 84
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 67
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 61
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 57
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 56
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 56
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 55
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 52
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 52
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 46
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 33
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 18
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 284 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 6 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
74.4%
Operating Margin
4.0%
Net Margin
6.0%
EBITDA Margin
8.2%
ROE
4.7%
ROA
3.4%
ROIC
—
EPS
$0.33
Cash
$100.09M
Total Debt
—
Current Ratio
5.03
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$39.30
Estimated Fair Value (DCF)
$10.70
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-72.8%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
18.9%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 18.9% | $29.43M | $27.00M |
| 2 | 14.8% | $33.78M | $28.44M |
| 3 | 10.7% | $37.40M | $28.88M |
| 4 | 6.6% | $39.87M | $28.25M |
| 5 | 2.5% | $40.87M | $26.56M |
Base FCF (last actual year)
$24.75M
Terminal Value
$644.45M
Present Value of Terminal Value
$418.85M
Enterprise Value
$557.97M
Net Debt
$0
Equity Value
$557.97M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$6.80
Tangible Book Value per Share (Tangible NAV)
$6.69
Sentiment based on basic keywords (not AI) — 13 positive, 6 neutral, 1 negative out of the last 20 articles.
SeekingAlpha · 15.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
ChartMill · 5.9.2026
ChartMill · 14.8.2026
MarketBeat · 13.8.2026
GlobeNewswire · 13.8.2026
ChartMill · 11.8.2026
IPO-Edge.com · 3.8.2026
Yahoo · 3.8.2026
Benzinga · 31.7.2026
MT Newswires · 31.7.2026
Benzinga · 31.7.2026
SeekingAlpha · 31.7.2026
Benzinga · 31.7.2026
MarketBeat · 30.7.2026
Yahoo · 30.7.2026
Zacks · 30.7.2026
Yahoo · 30.7.2026
Vericel Corporation (VCEL) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
VCEL currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, VCEL's estimated fair value is $10.70, which is 72.8% below the current price of $39.30. This is one valuation model among several signals in the fair-value category, not a price target.
VCEL's technical score is 43/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 60.0%; Free cash flow growth: 525.9%; Net income growth: 59.4%.
Based on the real signals StockIQ computed: Estimated fair value: $10.70 vs. price $39.30 (-72.8%); Calmar: 0.09 (3y annualized return 4.5% / max drawdown 52.5%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for VCEL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Open Market Sale | 12.8.2026 | 7,000 | -7,000 | $44.53 |
| MCLAUGHLIN KEVIN F | Exercise of Derivative Securities | 12.8.2026 | 7,000 | +7,000 | — |
| MCLAUGHLIN KEVIN F | Exercise of Derivative Securities | 12.8.2026 | 7,000 | +7,000 | $13.05 |
| MCLAUGHLIN KEVIN F | Open Market Sale | 12.8.2026 | 18,300 | -7,000 | $44.53 |
| MCLAUGHLIN KEVIN F | Exercise of Derivative Securities | 12.8.2026 | 25,300 | +7,000 | $13.05 |
| MCLAUGHLIN KEVIN F | Exercise of Derivative Securities | 12.8.2026 | 7,000 | +7,000 | — |
| Halpin Michael | Open Market Sale | 3.8.2026 | 10,000 | -10,000 | $46.84 |
| Halpin Michael | Exercise of Derivative Securities | 3.8.2026 | 10,000 | +10,000 | — |
| Halpin Michael | Exercise of Derivative Securities | 3.8.2026 | 10,000 | +10,000 | $16.66 |
| Halpin Michael | Exercise of Derivative Securities | 3.8.2026 | 26,394 | +10,000 | $16.66 |
| Halpin Michael | Open Market Sale | 3.8.2026 | 16,394 | -10,000 | $46.84 |
| Halpin Michael | Exercise of Derivative Securities | 3.8.2026 | 26,250 | +10,000 | — |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 2,500 | +2,500 | $29.82 |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 500 | +500 | — |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 500 | +500 | $29.82 |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 1,500 | +1,500 | $34.90 |
| SIEGAL JONATHAN | Open Market Sale | 30.7.2026 | 500 | -500 | $48.90 |
| SIEGAL JONATHAN | Open Market Sale | 30.7.2026 | 1,500 | -1,500 | $48.90 |
| SIEGAL JONATHAN | Open Market Sale | 30.7.2026 | 2,500 | -2,500 | $48.90 |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 2,500 | +2,500 | — |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 1,500 | +1,500 | — |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 2,578 | +1,500 | $34.90 |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 3,578 | +2,500 | $29.82 |
| SIEGAL JONATHAN | Exercise of Derivative Securities | 30.7.2026 | 1,578 | +500 | $29.82 |
| SIEGAL JONATHAN | Open Market Sale | 30.7.2026 | 1,078 | -500 | $48.90 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,483,102 shares short as of 2026-09-15 · vs. 4,759,226 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
76.1% of trading volume this week was short selling, vs. 65.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology